Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(1.62)
# 3,148
Out of 4,842 analysts
14
Total ratings
58.33%
Success rate
-11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITOS iTeos Therapeutics | Downgrades: Equal-Weight | $13 → $12 | $10.17 | +17.99% | 6 | May 28, 2025 | |
| BCAX Bicara Therapeutics | Upgrades: Equal-Weight | $8 | $9.76 | -18.03% | 2 | May 23, 2025 | |
| MRUS Merus | Maintains: Overweight | $91 → $89 | $50.93 | +74.75% | 1 | May 8, 2025 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $29 → $26 | $9.22 | +182.00% | 2 | May 7, 2025 | |
| XNCR Xencor | Maintains: Overweight | $37 → $33 | $7.87 | +319.31% | 2 | Feb 28, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Initiates: Overweight | $34 | $27.04 | +25.74% | 1 | May 3, 2024 |
iTeos Therapeutics
May 28, 2025
Downgrades: Equal-Weight
Price Target: $13 → $12
Current: $10.17
Upside: +17.99%
Bicara Therapeutics
May 23, 2025
Upgrades: Equal-Weight
Price Target: $8
Current: $9.76
Upside: -18.03%
Merus
May 8, 2025
Maintains: Overweight
Price Target: $91 → $89
Current: $50.93
Upside: +74.75%
Arcus Biosciences
May 7, 2025
Maintains: Overweight
Price Target: $29 → $26
Current: $9.22
Upside: +182.00%
Xencor
Feb 28, 2025
Maintains: Overweight
Price Target: $37 → $33
Current: $7.87
Upside: +319.31%
Kiniksa Pharmaceuticals International,
May 3, 2024
Initiates: Overweight
Price Target: $34
Current: $27.04
Upside: +25.74%